Nexien Biopharma Return On Equity vs. Number Of Employees
| NXEN Stock | USD 0.01 0.01 35.00% |
For Nexien Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nexien Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nexien Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nexien Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nexien Biopharma over time as well as its relative position and ranking within its peers.
Nexien |
Nexien Biopharma Number Of Employees vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Nexien Biopharma's current stock value. Our valuation model uses many indicators to compare Nexien Biopharma value to that of its competitors to determine the firm's financial worth. Nexien Biopharma is regarded fifth in return on equity category among its peers. It is considered to be number one stock in number of employees category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nexien Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nexien Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nexien Number Of Employees vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Nexien Biopharma |
| = | -40.7 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Nexien Biopharma |
| = | 6 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Nexien Number Of Employees vs Competition
Nexien Biopharma is considered to be number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 570. Nexien Biopharma claims roughly 6.0 in number of employees contributing just under 2% to equities under Drug Manufacturers—Specialty & Generic industry.
Nexien Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Nexien Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nexien Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Nexien Biopharma's change in net profit over the period of time. It can combine multiple indicators of Nexien Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Nexien BioPharma, Inc. operates as a pharmaceutical company. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Nexien Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Nexien Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nexien Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nexien Biopharma's important profitability drivers and their relationship over time.
Use Nexien Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nexien Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nexien Biopharma will appreciate offsetting losses from the drop in the long position's value.Nexien Biopharma Pair Trading
Nexien Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Nexien Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nexien Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nexien Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nexien Biopharma to buy it.
The correlation of Nexien Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nexien Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nexien Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nexien Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Nexien Biopharma position
In addition to having Nexien Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 253 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nexien Pink Sheet
To fully project Nexien Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Nexien Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Nexien Biopharma's income statement, its balance sheet, and the statement of cash flows.